Platelet-Rich Plasma Therapy for Patellar Tendinopathy
United States30 participantsStarted 2017-04-25
Plain-language summary
The overall goal of this research is to find an effective treatment for patellar tendinopathy (PT). To achieve this, we will conduct a double-blinded randomized controlled trial to investigate if platelet-rich plasma is effective for treatment. Clinical (pain and function scores) and bio-mechanical (knee strength) measures will be correlated with disease modification changes assessed using conventional and novel quantitative magnetic resonance imaging (MRI) and ultrasound (US) techniques.
Who can participate
Age range18 Years – 39 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 18 and 39 years
✓. Chronic (\>3 months) PT
✓. Clinical examination consistent with PT
✓. MRI or US confirmation of PT
✓. Pain score of 3 or greater on a 10-point visual analogue scale
✓. Self-report failure of supervised physical therapy
✓. Self-report failure of at least 2 of the most common treatment options for PT (e.g. NSAIDs, relative rest, ice and bracing).
Exclusion criteria
✕. Inability to comply with study follow-up requirements
✕. History of bleeding disorders or other hematologic conditions
✕. Knee pain from other possible etiologies (e.g., degenerative joint disease, meniscal tear, ligament injury or reconstruction)
✕. Full or partial patellar tendon tear
✕. Current use of anticoagulation or immunosuppressive therapy
✕. Prior knee trauma requiring medical attention or surgery
✕. Worker's compensation injury
What they're measuring
1
Change in Measure of Pain Level: VISA-P Score
Timeframe: baseline, 16 weeks, 32 weeks, 52 weeks
2
Change in Measure of Activity Level: Tegner Activity Level Score